http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-624269-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de8ac59362ab9f951b3381ed4680a070
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de2584bef6b987ea987eb0bcc8d95afa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_63f293fb56e28b0c797fd31eb8c33ad4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9092c90fd86471f706dcc2ab78cb6295
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62f4f46129e80ef907c188099adbb95a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-653
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-215
filingDate 2014-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c989f18f49b7157980b6fd58475aedf9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9010c8294736cca0717956d7b37a28cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08d82cbbfa9d1b881599a249f5415052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d1a2caefb001dfbd18ec0a5a0e5e395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fba9da2568716f129a0d1e47ea3faca
publicationDate 2014-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NZ-624269-A
titleOfInvention Method for the treatment of hypercholesterolemia
abstract Provided are methods of treating hypercholesterolemia, hypertriglyceridemia, atherosclerosis and hypertriglyceridemia induced fatty liver and/or pancreatitis through the administration of Calebin A (3E)-4-(4-Hydroxy-3-methoxyphenyl)-2-oxo-3-buten-1-yl (2E)-3-(4-hydroxy-3-methoxyphenyl)acrylate).
priorityDate 2014-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416046836
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID637429

Total number of triples: 32.